Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that novel hexahydrobenzoquinolin compounds fully inhibited 5α-reductase activity in human genital skin fibroblasts, suggesting their potential for treating conditions like benign prostatic hyperplasia and male pattern baldness.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

This study found that certain molecular quantum descriptors can be directly correlated with the biological activity of benzo[c]quinolizin-3-ones, potentially aiding in the identification and design of active compounds.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.